Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
about
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Idarubicin and cytarabine in c ...... kemia Groups (protocol 06013).
@ast
Idarubicin and cytarabine in c ...... kemia Groups (protocol 06013).
@en
type
label
Idarubicin and cytarabine in c ...... kemia Groups (protocol 06013).
@ast
Idarubicin and cytarabine in c ...... kemia Groups (protocol 06013).
@en
prefLabel
Idarubicin and cytarabine in c ...... kemia Groups (protocol 06013).
@ast
Idarubicin and cytarabine in c ...... kemia Groups (protocol 06013).
@en
P2093
P2860
P1433
P1476
Idarubicin and cytarabine in c ...... ukemia Groups (protocol 06013)
@en
P2093
Constantijn Halkes
Dominik Selleslag
Dominique Bron
Frédéric Baron
Roel Willemze
Stefan Suciu
Theo de Witte
P2860
P304
P356
10.1007/S00277-015-2486-9
P577
2015-09-26T00:00:00Z